

**FACSIMILE COVER SHEET**  
**SALIWANCHIK, LLOYD & SALIWANCHIK**A Professional Association  
2421 N.W. 41st Street  
Suite A-1  
Gainesville, FL 32606Telephone (352) 375-8100  
Facsimile (352) 372-5800**RECEIVED**  
**CENTRAL FAX CENTER**

AUG 06 2004

**OFFICIAL****Examiner:** Celine X. Qian, Ph.D.**FROM:** David Saliwanchik**COMPANY:** U.S. Patent Office  
Art Unit 1636**DATE:** August 6, 2004**FAX NO.:** (703) 872-9306**NO. OF PAGES**  
**(INCLUDING COVER SHEET):** 11**SUBJECT/MESSAGE:**Serial No. 09/762,842; filed February 12, 2001  
Attorney Docket No. SPO-112

- 1) Request for Continued Examination Transmittal (RCE) (1 pages); and
- 1) Amendment under 37 CFR §1.111 (9 pages).

**THIS IS AN OFFICIAL DOCUMENT!**  
**PLEASE DELIVER TO EXAMINER QIAN IMMEDIATELY**

---

*The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.*

---

**If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.**

H:\DOC\FAXCOVER\PTO\QIAN-1636 .DOC\RES\la

PTO/SB/30 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	109/762,842
Filing Date	February 12, 2001
First Named Inventor	Akira Murasugi
Art Unit	1636
Examiner Name	Celine X. Qian, Ph.D.
Attorney Docket Number	SPO-112

**This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.**  
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1994, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

**1. Submission required under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

**2. Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

**3. Fees**

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to  
Deposit Account No. 19-0065
- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e) (\$770.00)
- ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	David R. Saliwanchik	Registration No. (Attorney/Agent)	31,794
Signature		Date	August 6, 2004

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on: **January 8, 2003**

Name (Print/Type)	David R. Saliwanchik	Date	August 6, 2004
Signature	<i>David Saliwanchik</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
CENTRAL FAX CENTER

AUG 06 2004

OFFICIAL

I hereby certify that this correspondence is  
being facsimile transmitted to the U.S. Patent  
and Trademark Office on the date shown below:

AMENDMENT UNDER 37 CFR §1.111

Examining Group 1636

Patent Application

Docket No. SPO-112

Serial No. 09/762,842

August 6, 2004David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Celine X. Qian, Ph.D.  
Art Unit : 1636  
Applicants : Akira Murasugi, Yukio Asami, Isao Kido, Hideshi Kumai  
Serial No. : 09/762,842  
Filed : February 12, 2001  
Conf. No. : 1096  
For : High Level Secretory Expression System of Intact MK Family Protein

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

AMENDMENT UNDER 37 C.F.R. §1.111

Sir:

This Amendment is being submitted with a Requested for Continued Examination (RCE) in the above-referenced patent application. Please amend the above-identified patent application as follows:

**Amendments to the Claims** are reflected in the listing of claims beginning on page 2 of this paper.

**Remarks/Arguments** follow the amendment sections of this paper.

J:\sh-resp\spo\112-prelamend.doc\DNB\la